Dual Responsive poly(vinyl caprolactam)-Based Nanogels for Tunable Intracellular Doxorubicin Delivery in Cancer Cells

In this work, doxorubicin (Dox)-encapsulated poly(vinyl caprolactam) (PVCL)-based three-dimensional nanogel networks were developed and were crosslinked with disulfide linkages. The nanogels degrade rapidly to low molecular weight chains in the presence of the typical intracellular concentration of...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-04, Vol.14 (4), p.852
Main Authors: Rao, Kummara Madhusudana, Suneetha, Maduru, Kumar, Dachuru Vinay, Kim, Hyeon Jin, Seok, Yong Joo, Han, Sung Soo
Format: Article
Language:English
Subjects:
cancer cells
Cancer therapies
Cell culture
Chemotherapy
Cytotoxicity
Drug delivery systems
drug release
dual responsive
Emulsion polymerization
FDA approval
intracellular triggered
nanogels
Phase transitions
poly(vinyl caprolactam)
Polymers
Tissue engineering
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this work, doxorubicin (Dox)-encapsulated poly(vinyl caprolactam) (PVCL)-based three-dimensional nanogel networks were developed and were crosslinked with disulfide linkages. The nanogels degrade rapidly to low molecular weight chains in the presence of the typical intracellular concentration of glutathione. Doxorubicin (Dox) was successfully encapsulated into these nanogels. The nanogels have a high drug loading of 49% and can be tailored to 182 nm to deliver themselves to the targeted cells and release Dox under dual stimuli conditions, such as redox and temperature. By evaluating cell viability in the HepG2 cell line, we observed that Dox-loaded nanogels effectively killed the cancer cell. Fluorescence microscopy results show that the nanogels could easily be internalized with HepG2 cells. The results confirm that the nanogels destabilized in intracellular cytosol via degradation of disulfide bonds in nanogels networks and release of the Dox nearby the nucleus. These carriers could be promising for cancer drug delivery.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14040852